Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

AI partners Microsoft and OpenAI’s cooling relationship cools further with Amgen’s switch from Copilot to ChatGPT.

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

A 333-unit community, Hillcrest Apartments, will be developed directly across from Amgen’s headquarters in Thousand Oaks, ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

In the most recent trading session, Amgen (AMGN) closed at $280.35, indicating a +1.03% shift from the previous trading day.

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a slow | ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...